The historical rank and industry rank for Infinity Pharmaceuticals's Gross Margin % or its related term are showing as below:
INFIQ's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
Infinity Pharmaceuticals had a gross margin of 39.62% for the quarter that ended in Jun. 2023 => Competition eroding margins
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Infinity Pharmaceuticals had a gross margin of 39.62% for the quarter that ended in Jun. 2023 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Infinity Pharmaceuticals Gross Margin % Related Terms
Infinity Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INFIQ vs CLCS, RVLPQ, IVRN: Gross Margin % Comparison
For the Biotechnology subindustry, Infinity Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Infinity Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Infinity Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Infinity Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Infinity Pharmaceuticals (INFIQ) has a Gross Margin % of 39.62% as of Jun. 2023. Gross margin is the ratio of total gross profit to net sales. View historical data on Infinity Pharmaceuticals and its competitors.
Is Infinity Pharmaceuticals' Gross Margin % too high?
Infinity Pharmaceuticals' current Gross Margin % is 39.62%. The Biotechnology industry median Gross Margin % is 60.91. Infinity Pharmaceuticals' value of 39.62% is 35% below this industry median. Overall, Infinity Pharmaceuticals has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Infinity Pharmaceuticals' Gross Margin % compare to CLCS and RVLPQ?
Infinity Pharmaceuticals' Gross Margin % of 39.62% can be compared against companies in the Biotechnology industry. The industry median Gross Margin % is 60.91. Infinity Pharmaceuticals' value of 39.62% is 35% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Infinity Pharmaceuticals's current Gross Margin % of 39.62% is 35% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Infinity Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Infinity Pharmaceuticals's current Gross Margin % is 39.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infinity Pharmaceuticals stock overvalued right now?
Infinity Pharmaceuticals (INFIQ) has a current Gross Margin % of 39.62%. The current Gross Margin % is 39.62% and 35% below the Biotechnology industry median of 60.91. Infinity Pharmaceuticals' overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Infinity Pharmaceuticals (INFIQ), the current Gross Margin % is 39.62% as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company dedicated to developing novel medicines for people with cancer. It combines proven scientific expertise with a passion for developing novel small molecule drugs that target disease pathways for potential applications in oncology. It is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma, or PI3K-gamma.
16GF Score
Get the complete analysis for INFIQ
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INFIQ has been successfully added to your 
